Table 1:
Prospective global policy options considered for the economic analysis compared to reference cases RC2 and RC2*
| Policy name | Description | LI/LMI countries using OPV+IPV at T0 |
|---|---|---|
| Control scenarios | ||
| RC2 | 1 dose of IPV in 2019–2029 | 2019–2029 OPV+IPV |
| tOPVRISIA | 1 dose of IPV in 2019–2023 followed by tOPV use only from January 1, 2024 with pSIAs | 2019–2023 OPV+IPV 2024–2029 OPV-only |
| tOPVRI | 1 dose of IPV in 2019–2023 followed by tOPV use only from January 1, 2024 without pSIAs | 2019–2023 OPV+IPV 2024–2029 OPV-only |
| 2IPV2025 | 1 dose of IPV in 2019–2024 followed by 2 doses of IPV from January 1, 2025 | 2019–2024 OPV+IPV 2025–2029 OPV+2IPV |
| RC2noRestarts | 1 dose of IPV in 2019–2029 | 2019–2029 OPV+IPV |
| Eradication scenarios | ||
| RC2* | 1 dose of IPV in 2019–2024 followed by 2 doses of IPV from January 1, 2025 | 2019–2024 OPV+IPV 2025–2029 IPV/IPV |
| 1IPV2025 | 1 dose of IPV in 2019–2029 | 2019–2024 OPV+IPV 2025–2029 IPV |
Abbreviations: HI, high-income; IPV, inactivate poliovirus vaccine; LMI, lower middle-income; LI, low-income; OPV, oral poliovirus vaccine; OPV+IPV, routine immunization schedule that delivers IPV with the third OPV dose; RC, reference case; RC2, control reference case; RC2*, WPV1 eradication reference case; T0, beginning of analytical time horizon (i.e., January 1, 2019); Tend, end of analytical time horizon (i.e., December 31, 2029); tOPV, trivalent OPV; tOPVRISIA, 1 dose of IPV in 2019–2023 followed by tOPV use only from January 1, 2024 with pSIAs; tOPVRI, 1 dose of IPV in 2019–2023 followed by tOPV use only from January 1, 2024 without pSIAs; VAPP, vaccine-associated paralytic polio; VDPV, vaccine-derived poliovirus; WPV1, serotype 1 wild poliovirus; 1IPV2025, 1 dose of IPV in 2019–2029; 2IPV2025, 1 dose of IPV in 2019–2024 followed by 2 doses of IPV from January 1, 2025